VLS Retatrutide

Description

Buy VLS Retatrutide UK | Triple-Agonist Research Peptide

VLS Retatrutide UK is a high-purity synthetic research peptide available from MedExpress from £135. Retatrutide (also referred to as LY3437943) is currently one of the most researched next-generation peptide compounds, known for its unique triple-agonist activity at GLP-1, GIP and glucagon receptors simultaneously.

This product is supplied strictly for laboratory research and analytical purposes only. It is not approved for human or veterinary use. All orders are intended for controlled scientific environments. By purchasing, you confirm this material will be used solely for lawful research applications.

What is Retatrutide?

Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly, currently undergoing Phase 3 clinical trials (TRIUMPH programme) for obesity and type 2 diabetes. It belongs to a new generation of compounds known as triple hormone receptor agonists — acting on three metabolic pathways simultaneously rather than one or two.

The three receptor targets are:

• GLP-1 (Glucagon-Like Peptide-1) — regulates appetite and insulin secretion
• GIP (Glucose-Dependent Insulinotropic Polypeptide) — supports insulin release and fat metabolism
• Glucagon receptor — involved in energy expenditure and hepatic glucose production

This triple-agonist mechanism is what distinguishes Retatrutide from existing dual-agonist compounds such as Tirzepatide (Mounjaro) and single-agonist compounds such as Semaglutide (Wegovy/Ozempic).

VLS Retatrutide Research Profile

Phase 2 clinical trial data for Retatrutide has shown some of the most significant findings in this compound class to date. At the highest dose over 48 weeks, participants in Phase 2 trials lost an average of 24.2% of starting body weight, with 26% of participants losing 30% or more of their initial weight.

Phase 3 TRIUMPH-1 trial topline results published in May 2026 showed participants on the highest dose lost an average of 28.3% of their body weight at 80 weeks, with 45.3% of patients losing 30% or more — a threshold previously only achievable with bariatric surgery.

These figures represent the highest average weight reduction data observed in this drug class to date, making Retatrutide one of the most closely watched compounds in metabolic research.

How Does Retatrutide Work?

As a triple-agonist, Retatrutide activates three distinct hormone receptor pathways involved in appetite regulation, glucose metabolism and energy expenditure:

• GLP-1 activation slows gastric emptying and reduces appetite signals
• GIP activation supports insulin sensitivity and fat tissue metabolism
• Glucagon activation increases energy expenditure and reduces hepatic fat accumulation

The combined effect on all three pathways is theorised to produce more pronounced metabolic effects than single or dual receptor targeting alone.

VLS Retatrutide vs Other Research Peptides

Researchers frequently compare Retatrutide alongside other compounds in this class:

• Retatrutide (triple-agonist) — GLP-1 + GIP + glucagon receptor activity, Phase 3 trials, 28.3% average weight loss at 80 weeks (TRIUMPH-1 data)
• Tirzepatide (dual-agonist) — GLP-1 + GIP receptor activity, licensed as Mounjaro for weight management
• Semaglutide (single-agonist) — GLP-1 receptor only, licensed as Wegovy for weight management and Ozempic for type 2 diabetes

For those researching licensed treatment options, MedExpress also stocks Mounjaro (Tirzepatide) and Wegovy (Semaglutide), both MHRA-approved and available with a private prescription.

Retatrutide UK Availability

As of June 2026, Retatrutide is not MHRA-approved and is not licensed for medical use in the UK or anywhere else in the world. Phase 3 trial results have now been published, with potential regulatory submissions expected in 2026, and possible first private-market launches internationally in 2027, with potential early UK private availability if approved.

VLS Retatrutide is supplied by MedExpress strictly as a research-grade peptide for laboratory and analytical use only, in accordance with UK research chemical regulations.

Product Specifications

• Product name: VLS Retatrutide
• Compound: Retatrutide (LY3437943)
• Receptor activity: GLP-1, GIP, Glucagon (triple-agonist)
• Form: Injectable research peptide pen
• Supplied for: Laboratory and research use only
• Price: From £135

Important Safety & Legal Disclaimer

VLS Retatrutide is supplied strictly as a research chemical for use in controlled scientific and laboratory environments. It is not intended for human consumption, medical treatment, self-administration, diagnostics or veterinary use. No claims are made regarding its safety, efficacy or suitability for any medical purpose.

Retatrutide is currently an investigational compound and is not licensed by the MHRA or any regulatory authority worldwide. Purchasers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.

Adverse reactions or concerns related to research chemicals can be reported via the MHRA Yellow Card Scheme.

Frequently Asked Questions About VLS Retatrutide UK

What is VLS Retatrutide?

VLS Retatrutide is a high-purity research-grade peptide supplied by MedExpress for laboratory use. It contains Retatrutide (LY3437943), a synthetic triple-agonist compound with activity at GLP-1, GIP and glucagon receptors, currently in Phase 3 clinical trials.

Is Retatrutide approved for use in the UK?

No. Retatrutide is not approved by the MHRA and is not licensed for medical use in the UK or anywhere else in the world as of June 2026. VLS Retatrutide is supplied strictly as a research chemical for laboratory purposes only.

How does Retatrutide differ from Mounjaro or Wegovy?

Mounjaro (Tirzepatide) is a dual-agonist targeting GLP-1 and GIP receptors, and is MHRA-approved for weight management. Wegovy (Semaglutide) targets GLP-1 only and is also MHRA-approved for weight loss. Retatrutide targets all three receptors — GLP-1, GIP and glucagon — and is still in clinical development. It is not yet licensed for any medical use.

What were the Phase 3 Retatrutide trial results?

TRIUMPH-1 Phase 3 trial data published in May 2026 showed participants on the highest dose lost an average of 28.3% of body weight at 80 weeks, with 45.3% of patients achieving 30% or more weight loss — results comparable to bariatric surgery outcomes.

When will Retatrutide be available in the UK as a licensed medicine?

Regulatory submissions to the MHRA are expected in 2026–2027. If approved, earliest UK private availability is projected for 2027, with wider NHS availability potentially following in 2028 or later, subject to NICE review.

Can I use VLS Retatrutide for weight loss?

No. This product is supplied strictly for research purposes only and must not be used for human consumption or any medical purpose. For MHRA-approved weight loss treatments, please see Mounjaro and Wegovy.

Explore Licensed Weight Loss Treatments

If you are looking for MHRA-approved weight loss injections available now, browse our range including Mounjaro (Tirzepatide) from £129 and Wegovy (Semaglutide) from £99. Both are available following a free online consultation with our clinical team.

VLS Retatrutide is supplied for research and laboratory use only. MedExpress makes no medical claims regarding this product. This page is for informational purposes only. Always ensure compliance with applicable laws and regulations in your jurisdiction.